AstraZeneca Got Positive Results From Trial for Leukemia Drug Calquence
June 07 2021 - 02:45AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Monday that the Calquence drug-inhibitor
showed improvements in atrial fibrillation when compared with
ibrutinib in previously treated adult patients with chronic
lymphocytic leukemia.
The pharmaceutical giant said Calquence also proved to give
favorable tolerability at four years.
The company said these final results of Calquence come from the
head-to-head elevate-rr phase 3 trial.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 07, 2021 02:30 ET (06:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024